Simultaneous Integrated Boost (SIB)- IMRT

Status Completed

Clinical Trial Summary

The objective of the study is to assess the feasibility of increasing dose of irradiation with IMRT using a SIB approach over 6 weeks.

The primary endpoint of the study will be acute toxicity assessed during treatment and during the first 3 months following the completion of radiotherapy The secondary endpoint will include loco-regional control, disease-free survival, survival and late toxicity at 2 years after completion of radiotherapy

Clinical Trial Description

Loco-regional failures remain a major concern following irradiation of locally advanced head and neck cancers. This has led radiation oncologists to investigate novel approaches offering better therapeutic indexes. Modification of dose fractionation schedules can improve the therapeutic outcome by using accelerated or hyperfractionated regimes -Ang, 1990; Ang, 1998; Fu, 2000; Gwozdz, 1997-. Intensity Modulated Radiation Therapy (IMRT) technique allows the planning and irradiation of different targets at different dose levels in a single treatment session, instead of successive treatment plans. With conventional 2D radiotherapy, both normal tissues and tumors are irradiated with a similar dose per fraction of 1.8-2 Gy, whereas with IMRT dose gradients are introduced in such a manner that normal tissues receive a much lower dose per fraction. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00389727
Study type	Interventional
Source	Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact
Status	Completed
Phase	Phase 2
Start date	September 24, 2004
Completion date	May 26, 2008

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02743832` - A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.	N/A
Active, not recruiting	`NCT02229656` - Olaparib and Radiotherapy in Head and Neck Cancer	Phase 1
Recruiting	`NCT02328391` - STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE	N/A
Completed	`NCT00534950` - Randomized Multicenter Study of 5 vs 6 Weekly Fraction of RT in the Treatment of SCC of the Head and Neck	N/A
Completed	`NCT00875381` - Analysis of Melanocytes (Pigment Cells) in Sun-Exposed Skin	N/A
Terminated	`NCT00073450` - Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)	Phase 2
Terminated	`NCT01441128` - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer	Phase 1
Recruiting	`NCT05970497` - A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT01362127` - Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia	Phase 2
Completed	`NCT00240682` - Study of Cetuximab in Squamous Cell Carcinoma of the Skin Expressing EGFR	Phase 2
Terminated	`NCT02254044` - Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus	Phase 1
Active, not recruiting	`NCT00829192` - Phase II AK Study in Organ Transplant Patients	Phase 2
Completed	`NCT00313027` - Cervical Nodal Mets in Squamous Cell Carcinoma of H&N - MRI, FDG-PET, & Histopathologic Correlation	N/A
Completed	`NCT00539630` - TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN	Phase 3
Recruiting	`NCT04564989` - Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associated OPSCC
Not yet recruiting	`NCT06094829` - Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa
Recruiting	`NCT04481256` - TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY	N/A
Recruiting	`NCT06295809` - A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)	Phase 2/Phase 3
Active, not recruiting	`NCT02664935` - National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer	Phase 2
Terminated	`NCT02438995` - Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck	Phase 1